Arbutus Biopharma (ABUS) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Arbutus Biopharma is set to present at the Jefferies London Healthcare Conference to discuss its innovative approaches in treating chronic hepatitis B virus. The company’s pipeline includes promising treatments like the RNAi therapeutic imdusiran and an oral PD-L1 inhibitor, which are in crucial stages of clinical trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
